Cash and cash equivalents (USD)

Accounts receivable (USD)

Inventory (USD)

Deferred offering costs (USD)

Prepaid expenses (USD)

Total current assets (USD)

Intangible assets, net (USD)

Right-of-use asset (USD)

Property and equipment, net (USD)

Total assets (USD)

Accounts payable (USD)

Accrued expenses and other liabilities (USD)

Total current liabilities (USD)

Warrant liability (USD)

Operating lease liability, long term (USD)

Total liabilities (USD)

Common stock (USD)

Additional paid–in capital (USD)

Accumulated deficit (USD)

Total stockholders’ equity (USD)

Total liabilities and stockholders’ equity (USD)

426f52e85fc4ba8947d00dfe879ad1246f0b0f7dff93bde0eb25252873687674

Product Revenue (USD)

Cost of Product Revenue (USD)

Product Gross Profit (USD)

License Revenue (USD)

Collaborations Revenue (USD)

Selling, General and Administrative Expenses (USD)

Research and Development Expenses (USD)

Total Operating Expenses (USD)

Income (Loss) from Operations (USD)

Fair Value Change in Warrant Liability (USD)

Financing Costs (USD)

Other Income (USD)

Other Income, Net (USD)

Income (Loss) Before Income Taxes (USD)

Loss Before Income Taxes (USD)

Net Income (Loss) (USD)

e7c758560d495837519f7e77bec3927c78a94820c71a7a04e6a23b3fdfd17fd0

Net income (loss) [USD]

Amortization and depreciation [USD]

Amortization of deferred offering costs [USD]

Debt termination costs reclassed to financing activities [USD]

Stock-based compensation [USD]

Fair value change in warrant liability [USD]

Non-cash lease expense [USD]

Net cash provided by (used in) operating activities [USD]

Purchase of property and equipment [USD]

Net cash used in investing activities [USD]

Proceeds from issuance of common stock attributed to equity financings [USD]

Proceeds from issuance of warrants in connection with private placement [USD]

Proceeds from issuance of common stock in connection with at-the-market offering program [USD]

Issuance costs attributed to common stock and warrants issued in private placement [USD]

Issuance costs in connection with at-the-market offering program [USD]

Deferred issuance costs in connection with at-the-market offering program [USD]

Deferred issuance costs in connection with debt facility [USD]

Financing costs in connection with debt facility [USD]

Share repurchases for the payment of employee taxes [USD]

Net cash (used in) provided by financing activities [USD]

Net decrease in cash [USD]

Cash at beginning of period [USD]

Cash at end of period [USD]

de9f4e31e18fbc0bf7f4cd344b4ab75137e492594bb4de1a9ea46e891124ceb0

Product Revenue

- OneRF Products

- Other Products

Collaborations Revenue

License Revenue

Total Revenue

a3828039b88824c556dd5f338532cfc7bf6b54253f3235254f2b8aa13b9cfad7

Adjustments for Non-Cash Items (USD)

Stock-Based Compensation (USD)

Changes in Working Capital (USD)

Capital Expenditures (CapEx) (USD)

Proceeds from / Repayments of Debt (USD)

Share Repurchases (USD)

Dividend Payments (USD)

Net Change in Cash (USD)

2dac0c3073800cc185b679f214b00dc166b8df02449d7dcb79e19701b583f6a9

0c8ad00162bddca8e9830e81b8c69d8ba16f18b526eb60c3680538db1bc9cc18

67563b713da6c16cc21e441e8d6749c5a952d811d4649f3bfd3a75f0b94ff97a

Number of devices with FDA clearance (devices)

8cf13bafc18d83a8d41442aca0b8dd6c60ed4cbadf7d28918df796f4381710e4

NEUROONE MEDICAL TECHNOLOGIES (NMTC)

Financials